Tekla Life Sciences Investors (HQL) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear

Tekla Life Sciences Inves...

NYSE: HQL · Real-Time Price · USD
13.93
0.02 (0.14%)
At close: Aug 29, 2025, 3:59 PM
14.08
1.11%
After-hours: Aug 29, 2025, 05:16 PM EDT

Tekla Life Sciences Investors Cash Flow Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year Q2 2025 Q4 2024 Q2 2024 Q4 2023 Q2 2023 Q4 2022 Q2 2022 Q4 2021 Q2 2021
Period Ending Mar 31, 2025 Sep 30, 2024 Mar 31, 2024 Sep 30, 2023 Mar 31, 2023 Sep 30, 2022 Mar 31, 2022 Sep 30, 2021 Mar 31, 2021
Net Income
-47.23M n/a 11.18M 44.98M 33.75M -104.6K -20.04K 64.53K 93.79K
Depreciation & Amortization
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Stock-Based Compensation
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Working Capital
64.75K n/a n/a n/a n/a n/a n/a n/a n/a
Other Non-Cash Items
46.26M n/a -11.18M -44.98M -33.75M 104.6K 20.04K -64.53K -93.79K
Deferred Income Tax
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Change in Working Capital
-73.8K n/a n/a n/a n/a n/a n/a n/a n/a
Operating Cash Flow
-1.04M n/a n/a n/a n/a n/a -0.37 -0.74 -0.37
Capital Expenditures
-4 n/a n/a n/a n/a n/a n/a n/a n/a
Cash Acquisitions
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Purchase of Investments
-157.46M n/a n/a n/a n/a n/a n/a n/a n/a
Sales Maturities Of Investments
161.84M n/a n/a n/a n/a n/a n/a n/a n/a
Other Investing Acitivies
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Investing Cash Flow
4.39M n/a n/a n/a n/a n/a n/a n/a n/a
Debt Repayment
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Common Stock Repurchased
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Financial Acitivies
-8.41M n/a n/a n/a n/a n/a n/a n/a n/a
Financial Cash Flow
-8.41M n/a n/a n/a n/a n/a n/a n/a n/a
Net Cash Flow
n/a n/a 32.00 32.00 -545 -1.09K -545.74 -1.49 -0.74
Free Cash Flow
-1.04M n/a n/a n/a n/a n/a -0.37 -0.74 -0.37